2,333 reports of this reaction
5.2% of all BIMATOPROST reports
#3 most reported adverse reaction
OCULAR HYPERAEMIA is the #3 most commonly reported adverse reaction for BIMATOPROST, manufactured by Allergan, Inc.. There are 2,333 FDA adverse event reports linking BIMATOPROST to OCULAR HYPERAEMIA. This represents approximately 5.2% of all 44,865 adverse event reports for this drug.
Patients taking BIMATOPROST who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among BIMATOPROST users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for BIMATOPROST:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 2,333 FDA reports for BIMATOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 5.2% of all adverse event reports for BIMATOPROST, making it one of the most commonly reported side effect.
If you experience ocular hyperaemia while taking BIMATOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.